Revive Selects Pharm-Olam As Contract Research Organization For Infectious Disease Study

This evening, Revive Therapeutics (CSE: RVV) announced that the company has signed with a contract research organization to advance its previously announced clinical study into the use of Bucillamine as a treatment for infectious diseases. Concurrently, Revive also announced the appointment of Dr Kelly McKee Jr. to the role of Chief Scientific Officer, as well as the appointment of Dr Onesmo Mpanju to the role of regulatory affairs consultant to the firms clinical development team.

Pharm-Olam LLC has been chosen by Revive to act as the firms contract research organization (CRO) for the purpose of studying the aforementioned treatment in infectious disease. Pharm-Olam has conducted over 100 clinical studies to date with 19,000 patients at over 2,000 research sites. The firm will be responsible for advancing and conducting the future clinical trials in Bucillamine.

Dr Kelly McKee, now Chief Scientific Officer consultant for Revive, currently serves as a senior scientific and medical adviser for Pharm-Olam. Prior to this, he served as the firms Chief Medical Officer, as well as Vice President, Vaccines and Public Health for Infectious Diseases and Vaccines Center of Excellence at IQVIA. His work with infectious diseases spans over thirty years, beginning in 1981 with the US Army Medical Research Institute of Infectious Diseases.

Dr Mpanju comparatively has 28 years of experience in biopharmaceutical research and development, with his most recent role being that of a reviewer for the US Food and Drug Administration. His extensive consultation work has been utilized by the likes of the Bill & Melinda Gates Foundation and the U.S. National Institutes of Health, making the role of a regulatory affairs consultant the perfect fit for him.

Pharm-Olam has the proven experience in managing infectious disease clinical studies, a scalable ecosystem for expediting and completing clinical studies on time and on budget, and most importantly they have an infectious disease team of experts with the addition of Dr. McKee and Dr. Mpanju who will develop and oversee Revive’s clinical study and its expeditious submission of our IND with the FDA.

Michael Frank, Chief Executive Officer of Revive

The announcement of the appointment of a contract research organization for Revive follows yesterdays news that Revive has signed Dr David Boulware as a scientific adviser to the firm. Dr Boulware has significant experience in the field of infectious disease, and is currently the principal investigator in a COVID-19 clinical trial.

Revive Therapeutics last traded at $0.08 on the CSE.

FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.